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Previous results have demonstrated addition of long-acting /3z-adrenergic agonists to be beneficial in asthma 
patients already receiving inhaled corticosteroid. The purpose of this study was to determine, qualitatively as well as 
quantitatively, the steroid-sparing properties of salmeterol in stable asthma patients receiving maintenance inhaled 
corticosteroids (800-1600 pg day- ‘). 
In these patients, the daily dose of beclomethasone dipropionate was reduced by 200 pg each week until asthma 
deteriorated, with the minimal acceptable dose (MAD) being defined as the dose one step above deterioration 
(sensitivity period). Following this, patients received three times the MAD for 2 weeks. Patients were randomized to 
receive either salmeterol 50 ,ug twice daily or placebo and the MAD was again determined (treatment period). 
Forced expiratory volume in 1 set (FEV1) was measured each week. Morning and evening peak expiratory flow 
(PEF), symptom score and use of bronchodilator were recorded each day. 
Fifteen patients received salmeterol and 19 placebo. The MAD was significantly lower in the salmeterol group 
compared with placebo during the treatment period (P<O.Ol). A 50% reduction of the MAD was achieved by 
more patients treated with salmeterol than placebo (P= 0.001). Salmeterol caused a significantly greater reduction 
in daytime symptom score and use of as-needed p2-agoinist therapy between sensitivity and treatment periods 
compared with placebo (PcO.05 for both). 
The results demonstrate, that the addition of salmeterol to corticosteroid treatment offers a clinically relevant 
potential for reduction of inhaled corticosteroid dose in steroid sensitive asthmatics. 
RESPIR. MED. (1999) 93, 863-868 0 1999 HARCOURT PUBLISHERS LTD 
____- ,,..” _,,_ __“_,~. __ _.,_ _” _ _ “,“,, __ _,____“, .;, _ ,.,, l ,_ .-,,_..i,ll ___,._ ,,“, . _ _li “_ -_- .- - -_-.- i_l .‘. ll-.“._.x_ _ ‘x _- “I - .-__ , .__I”(._- “_ I-._ -_^- 
Introduction 
The use of inhaled corticosteroids as a first-line treatment 
for asthma is well established. If patients remain sympto- 
matic during low- to moderate-dose inhaled corticosteroid 
therapy, previous recommendations have been to increase 
the dose of corticosteroid. However, recent guidelines 
propose an alternative strategy, i.e. the addition of a 
long-acting bronchodilator when symptoms persist (1,2). 
Salmeterol xinafoate is a highly selective, long-acting /?2- 
agonist that can be administered by inhalation. Regular 
treatment of asthma with salmeterol has been shown to 
reduce symptoms and improve lung function (3-6). Long- 
term clinical studies have indicated that in patients 
remaining symptomatic on inhaled corticosteroid therapy, 
the addition of salmeterol to ongoing inhaled corticosteroid 
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therapy is superior to doubling the dose of the inhaled 
corticosteroid (7,8). However, the corticosteroid level at 
which to commence salmeterol treatment and, particularly, 
the extent to which the asthma patient can clinically benefit 
from such treatment remain unclear. Furthermore, it is 
unknown whether patients with stable asthma receiving 
inhaled corticosteroid treatment would benefit from salme- 
terol treatment. 
The present study was conducted to determine whether 
salmeterol had steroid-sparing properties in stable asthma 
patients already receiving maintenance inhaled corticoster- 
oids. 
Methods 
PATIENTS 
All patients were diagnosed with having asthma (9) and 
achieved the criteria of stable asthma defined for this study 
(Table 1). For all patients entering the study their asthma 
was controlled by a dose of inhaled corticosteroid 
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TABLE 1. Definition of stable asthma 
At least five out of the six criteria in each section must be fullfilled: 
I 
1) At the end of the baseline period: 
a) FEVi > 60% of predicted normal (before /I*-agonist) and during the last seven days of the period; 
b) mean morning PEF > 60% of predicted normal (before &agonist); 
c) mean evening PEF > 60% of predicted normal (before /?2-agonist); 
d) diurnal variation of PEF < 20% on each day; 
e) total symptom score 5 2 on each day; 
f) total daily use of salbutamol Il.2 mg on average. 
2) In all other periods: 
a) FEVi > 60% of predicted normal (before /?z-agonist) and during the last three days of the period; 
b) mean morning PEF > 60% of predicted normal (before &agonist) and within 80% of baseline morning PEF; 
c) mean evening PEF > 60% of predicted normal (before &agonist) and within 80% of baseline evening PEF; 
d) diurnal variation of PEF<20% on each day; 
e) total symptom score 5 2 on each day; 
f) total daily use of salbutamol 11.2 mg on average and less than 0.6 mg in addition to baseline average. 
FEVi: forced expiratory flow in 1 set; PEF: peak expiratory flow rate. 
(beclomethasone dipropionate (BDP) or budesonide) of 
80&1600 pg daily. Patients were excluded from the 
treatment period of the study if their asthma remained 
stable when the dose of inhaled corticosteroid had been 
reduced to zero. 
STUDY DESIGN 
This was a multicentre, double-blind, randomized, placebo- 
controlled trial. During the study period, patients attended 
the clinic each week for evaluation of asthma deterioration. 
At each visit FEVi was measured by spirometry (Vitalo- 
graph@, Spiropharma, Copenhagen, Denmark). In addi- 
tion, patients kept a diary card in which they recorded 
morning and evening PEF, asthma symptom score (day and 
night-time), the need for rescue /&agoinist medication and 
any adverse events. PEF was measured every morning 
and evening using a MiniWright@ (Spiropharma) peak flow 
meter. Daytime symptoms were scored using a scale 
ranging from 0 (no symptoms) to 5 (disabling symptoms), 
and at night-time using a scale ranging from 0 (no 
symptoms) to 4 (severe symptoms). 
The study consisted of five periods (Fig. 1). During the 
baseline period of 2 weeks, patients received BDP via a 
Diskhaler@ (GlaxoWellcome, London, U.K., at a dose 
equivalent to their previous corticosteroid dose. If using 
budesonide, this was changed to BDP at a 1:l ratio. 
Throughout the study, patients were allowed to use 
salbutamol 200 pg per actuation via a Diskhaler@ as 
needed in addition to BDP and study medication. Patients 
meeting the entry criteria for stable asthma (Table 1) 
progressed to the ‘sensitivity period’. In this period, the 
daily dose of inhaled corticosteroid for each patient was 
reduced by 200 pg each week. Reduction in the dose of 
inhaled corticosteroid continued until asthma became 
unstable, i.e. patients did not achieve the criteria for stable 
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FIG. 1. Study design. MADr and MADn are the minimal 
acceptable dose of inhaled corticosteroid in sensitivity and 
treatment periods, respectively. AW indicates asthma 
worsening. 
asthma. The minimal acceptable does (MAD) of BDP was 
defined as the dose one step above the dose resulting in 
unstable asthma. Patients who were able to completely 
withdraw from corticosteroid therapy without their asthma 
becoming unstable were excluded. Patients whose asthma 
became unstable were treated with a dose of inhaled 
corticosteroid that was three times the MAD (maximum 
dose level 3000 pg daily) for 2 weeks. Patients, who were 
stable at the end of the second week, were then randomized 
to either salmeterol 50 pg twice daily or placebo (treatment 
period). The daily dose of BDP was again reduced by 
2OOpg each week and the MAD determined. A 2-week 
follow-up period on appropriate medication concluded the 
study. 
STATISTICS 
All statistical analyses were carried out using SAS software 
(v. 6.11, SAS Institute, Carg, NC, U. S. A.). The proportion 
of patients that decreased their use of corticosteroids by at 
least 50% during the treatment period was analysed using a 
chi-square test. The MADs in the treatment period of the 
two treatment groups, as well as the difference between 
MADs during treatment and sensitivity periods, were 
analysed using a Wilcoxon 2-sample test with normal 
approximation. 
Lung function parameters (morning and evening PEF 
and FEVi) were tested by analysis of variance. PEF was 
analysed as the mean of the last three recordings while 
receiving the MAD. This procedure was also carried out for 
day and night-time symptom scores and use of rescue 
bronchodilator medication. These variables, as well as lung 
function parameters, were all analysed using logistic 
regression (proportional odds model). 
ETHICS 
The study was approved by the local scientific ethics 
committee (County of Aarhus), as well as the Danish 
National Board of Health. All patients gave informed 
consent in writing before entering the study. 
Results 
In total, 77 patients aged 19-65 years entered the study. All 
patients’ asthma was controlled by a dose of inhaled 
corticosteroid of 800-1600 ,ug daily. Forty-three patients 
were excluded at the end of the sensitivity period; the most 
common reason for exclusion was complete withdrawal of 
corticosteroid treatment (36 patients). Thirty-four patients 
were randomized to study medication. Fifteen patients 
received salmeterol and 19 patients received placebo. 
Baseline characteristics of patients are listed in Table 2. 
No significant differences in baseline characteristics were 
found between the two treatment groups. 
There was no significant difference in corticosteroid dose 
at baseline between the two groups. No difference in the 
MAD of corticosteroid was seen in the sensitivity period 
TABLE 2. Baseline characteristics of study population 
Characteristic Placebo Salmeterol Total 
Sex (m/f) 
Mean age (years) 
Smokers (n) 
Patients with an 
allergy (n) 
Mean asthma 
duration (yr) 
Mean FEVi 1 
(% predicted) 
Mean BDP dose 
(pg daily) 
1019 S/l0 15/19 
43.0 45.0 43.9 
9 5 14 
9 6 15 
12.9 15.4 14.0 
2.98 (86.7) 2.80(86.1) 2.90(86.4) 
1179 1280 1224 
FEVi: forced expiratory volume in 1 set; BDP: beclo- 
methasone dipropionate. 
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between patients randomized to salmeterol or placebo 
(Fig. 2). During the treatment period the MAD of 
corticosteroid was significantly lower in salmeterol-treated 
patients compared with those receiving placebo (P<O.Ol). 
Comparison of the MAD difference of salmeterol and 
placebo treatment between the sensitivity and treatment 
periods revealed a larger difference in the treatment period 
(PcO.01). The difference in MADs between the treatment 
and sensitivity periods (Table 3) was significantly larger in 
the salmeterol group compared to placebo (P = 0.01). 
The number of patients in each treatment group who 
were able to reduce their MAD by at least 50% during the 
treatment period was significantly greater in the salmeterol- 
treated group compared to the placebo-treated group 
(P = 0.001) (Fig. 3). 
The treatment given, whether salmeterol or placebo, did 
not influence lung function. FEV, and morning and 
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FIG. 2. The dose of inhaled corticosteroid during baseline 
and the minimal acceptable doses of inhaled 
corticosteroid during the sensitivity and treatment periods 
(MAD1 and MAD& in patients receiving either placebo 
(0) or salmeterol 50 pg twice daily (m). Results are 
expressed as mean (SE). *P< 0.01, n.s.: no significance. 
TABLE 3. Difference between periods (treatment-sensitiv- 
ity) for the two treatment groups 
Placebo Salmeterol P 
MAD hid 42 (118) -253 (196) < 0.01 
Morning PEF 3.7 (8.5) 17.4 (9.6) n.s. 
(1 min-‘) 
Evening PEF 3.2 (9.6) 14.1 (10.7) n.s. 
(1 min- ‘) 
FEVi (ml) -40 (170) 160 (210) n.s. 
Daily use of 42 (54) -214 (102) < 0.05 
salbutamol (pg) 
Results are given as mean (SE). MAD: minimal acceptable 
dose; PEF: peak expiratory flow; FEV,: forced expiratory 
volume in 1 sec. 
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FIG. 3. Number of patients able to reduce their minimal 
acceptable dose of inhaled corticosteroid by at least 50% 
or less than 50% during treatment with either placebo (0) 
or salemterol 50 pg twice daily (I). **: P= 0.001. 
evening PEFs in the treatment period were not significantly 
different from those observed during the sensitivity period, 
when comparing treatment groups (Table 3). 
Salmeterol-treated patients experienced significantly few- 
er symptoms during the daytime (P<O.Ol) and more days 
without symptoms (P< 0.001) than placebo-treated pa- 
tients (Fig. 4). There was no difference between the two 
treatments with regard to night-time symptom score (data 
not shown). 
Daily use of as needed bronchodilator medication 
increased slightly between sensitivity and treatment periods 
for the patients receiving placebo, whereas the salmeterol- 
treated group had a marked decrease in salbutamol 
consumption. Daily use of as needed salbutamol (Table 3) 
was significantly lower in salmeterol--compared with 
placebo-treated patients (P-C 0.05), 
No differences of steroid dosage and lung function 
parameters were observed between treatment groups at 
the end of the high dose period. 
.,hi d-3 
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Change in daytime symptom score 
Fig. 4. Median change in daytime asthma symptom scores 
between treatment and sensitivity periods (treatment- 
sensitivity) in patients treated with either placebo (0) or 
salmeterol 50 fig twice daily (M). 
In the placebo-treated group, patients had significantly 
lower morning PEF (P<O.O5), increased daytime symptom 
score (P-cO.05) and more frequently used as needed 
bronchodilator medication (P < 0.05) during the treatment 
period compared with baseline (data not shown). No such 
differences were observed in the salmeterol-treated group. 
There was no difference between the two treatment 
groups in the incidence of adverse events during the study. 
A total of 82 adverse events were reported and only one was 
classed as serious: this was a placebo-treated patient 
experiencing syncope, which was unrelated to study 
medication. 
Discussion 
A number of large studies have shown the addition of a 
long-acting &agoinist, such as salmeterol or formoterol, to 
be an alternative to increasing the dose of inhaled 
corticosteroid in symptomatic asthma patients (7,8,10). 
Indeed, with regard to improving asthma symptoms, these 
studies have shown the addition of a long-acting &agoinist 
to be superior to doubling the dose of corticosteroid in 
unstable asthma patients. Significant improvements in 
symptom control following the addition of salmeterol have 
also been reported in patients with severe asthma who are 
being considered for oral corticosteroid treatment (11). 
The present study is the first to evaluate whether 
salmeterol has a steroid-sparing effect. It is possible that 
the weekly reduction in corticosteroid dosage might be too 
short a time period for asthma to deteriorate. However, the 
design of the study has previously proven useful (12) and in 
this study only the most steroid-sensitive patients were 
randomized to treatment, which strengthens the results of 
the study. 
A significantly greater decrease in the MAD of corticos- 
teroid could be obtained when patients were treated with 
salmeterol compared with placebo. This demonstrates the 
ability of salmeterol to reduce the dose of inhaled 
corticosteroid required in stable asthma patients without 
affecting short-term disease control. This finding is sup- 
ported by a previous study showing salmeterol to allow a 
17% reduction in steroid dose compared with placebo, 
while maintaining disease control (13). Perhaps more 
importantly, 80% of salmeterol-treated patients were able 
to reduce their inhaled corticosteroid dose by more than 
half, compared with 21% of placebo-treated patients. Thus, 
the potential for reduction seemed clinically useful. 
Lung function parameters were stable throughout the 
study period in the salmeterol-treated group. Other studies 
have reported improved lung function in patients treated 
with salmeterol compared with those receiving higher doses 
of inhaled corticosteroid (7,8). However, the aim of this 
study was not to improve lung function but to maintain 
asthma control while reducing the dose in inhaled 
corticosteroid. 
Generally, the addition of salmeterol to existing therapy 
has resulted in reduced asthma symptoms and patients 
having less need for short-acting bronchodilators (7,8,13). 
Similar results were obtained for daytime symptom score in 
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this study even though the corticosteroid dosage was 
constantly being reduced. A little surprisingly, no treatment 
effect was seen for night-time symptoms, when comparing 
salmeterol and placebo groups. A possible explanation 
could be, that the asthma worsening elicited was intention- 
ally slight and short. 
Salmeterol treatment has proved beneficial in other 
aspects of asthma disease. Bronchial hyper-responsiveness 
has been shown to remain stable (8) or improve (13) in 
salmeterol-treated patients. This agrees with data demon- 
strating salmeterol to completely inhibit the increase in non- 
specific bronchial responsiveness following allergen chal- 
lenge in allergic asthma patients (14). Moreover, in patients 
with moderate-to-severe asthma the frequency of exacerba- 
tions were found to be equal whether they were treated with 
salmeterol in combination with inhaled corticosteroid or a 
double-dose of inhaled corticosteroid (7,8). 
Although inhaled corticosteroids are considered as safe 
and effective treatment for asthma, there has been some 
concern over long-term dose-dependent systemic and local 
side effects (15-l 8). In order to avoid potential side-effects, 
the dose of inhaled corticosteroid required for maintenance 
therapy should be as low as possible. The addition of 
salmeterol serves two purposes. Firstly, as illustrated by the 
results of this study, salmeterol treatment offers the 
possibility for further reduction in corticosteroid dose 
without affecting disease control. Secondly, the potential 
risk of under-treatment when reducing the inhaled corti- 
costeroid dose would be avoided by the addition of 
salmeterol. Although the reduction in corticosteroid dose 
in this study was performed using current standard 
measurements of disease activity, this data has shown that 
placebo-treated patients had significantly lower morning 
PEF and daytime symptom score, and a greater need for ‘as 
needed’ bronchodilator medication during the treatment 
period compared with baseline. Thus, reduction of the 
inhaled corticosteroid dose to an acceptable minimum level 
according to current disease parameters might increase the 
risk of some patients’ asthma becoming unstable and 
symptoms ensuing. 
At present, the reason for the steroid-sparing effect of 
salmeterol in unclear. One simple explanation would 
be that the bronchodilator activity of salmeterol enables 
the inhaled corticosteroid to reach the inflammatory site in 
the bronchi more effectively, and thereby reduces the 
steroid dose required. However, previous data using 
short-acting &agonist prior to inhalation of an corticos- 
teroid have not supported the theory of bronchodilatation 
permitting a reduction in steroid dose (19). 
The efficacy of inhaled corticosteroid treatment in 
asthma is based upon its anti-inflammatory activity. 
Indeed, the population selected in the present study 
represented the most steroid-sensitive asthma patients. It 
could, therefore, be speculated that the steroid-sparing 
effect of salmeterol was the result of an effect on the 
inflammatory process. Salmeterol has been reported to have 
some anti-inflammatory properties. In one study of 
corticosteroid-treated asthma patients, salmeterol caused 
a reduction in T-lymphocyte activation that was consider- 
ably greater and of longer duration than that observed with 
salbutamol (20). A separate study demonstrated a reduc- 
tion in blood eosinophil number in corticosteroid-treated 
asthma patients over a 12-month treatment period with 
salmeterol (21). In vitro, salmeterol has been shown to 
inhibit mediator secretion, i.e. histamine, leukotrienes and 
prostaglandins, from immunocompetent cells and tissues 
(22,23), supporting the anti-inflammatory effect of salme- 
terol. However, these findings are opposed by other studies, 
such as an unchanged bronchoalveolar lavage cell profile in 
asthma patients after salmeterol treatment (24). 
Concerns against the use of salmeterol for steroid- 
sparing purposes can be made as some studies have shown 
a reduction in Pz-adrenoceptor sensitivity and number to 
occur after treatment with long-acting &agonists (25,26). 
However, the importance of this finding remains unclear as, 
to date, there have been no reports of the clinical relevance 
of this finding. Large, longitudinal clinical studies have 
reported decreased consumption of short-acting &agonists 
(&lo, 13) and unaltered Pz-adrenoceptor sensitivity (21) 
following treatment with salmeterol. A possible explanation 
for the difference in findings could be that the studies 
presenting evidence of tachyphylaxis were performed on 
patients or healthy volunteers that were not regularly 
receiving &agonist therapy, whereas the clinical reality is 
that almost all asthma patients use short-acting /12-agonists 
to some extent. 
In conclusion, the results of this study clearly demon- 
strate a larger potential for reduction of inhaled corticos- 
teroid dose after addition of salmeterol to the treatment 
regimen compared with placebo. Quantitatively, this 
findings is potentially clinically relevant when considering 
the number of patients able to reduce inhaled corticosteroid 
dose by at least 50%. Salmeterol treatment did not affect 
lung function parameters, and, in fact, decreased daytime 
symptoms and need for bronchodilators. 
In contrast, placebo treatment resulted in poorer lung 
function, more symptoms and increased need for bronch- 
odilation, when compared to baseline, although steroid 
tapering was based on parameters according to current 
recommendations. 
Thus, the addition of salmeterol to existing corticosteroid 
treatment should be considered when attempting to obtain 
the lowest possible dose of inhaled corticosteroid required 
for optimal disease control in patients with moderate 
asthma. 
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